Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4423933 | 0.92 | POLB (0.45) | ALDH1A1MAPT | |
| SCHEMBL4421084 | 0.90 | POLB (0.40) | MEN1KMT2A | |
| SCHEMBL4424406 | 0.89 | MAPT (0.43) | MAPT | |
| SCHEMBL4434995 | 0.84 | MAPT (0.44) | MAPT | |
| SCHEMBL4434706 | 0.83 | POLB (0.37) | ALDH1A1MAPT | |
| SCHEMBL4432420 | 0.83 | ALDH1A1 (0.41) | MEN1KMT2AALDH1A1MAPTTSHR | |
| SCHEMBL4426464 | 0.80 | GAA (0.36) | ALDH1A1TSHR | |
| SCHEMBL4433277 | 0.80 | CA12 (0.40) | — | |
| SCHEMBL27412073 | 0.79 | POLB (0.41) | MEN1KMT2AMAPT | |
| SCHEMBL4428097 | 0.76 | NPC1 (0.44) | MEN1KMT2AALDH1A1TSHRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638505-B2 | Organophosphoric derivatives useful as anti-parasitic agents | UNIVERSITEIT GENT (BE) | 2009-12-29 | — | — | US | disclosed |
| US-20080312190-A1 | Such as 3-(N-hydroxyacetamido)-1-(3,4-dichlorophenyl)propylphosphonic acid; Antimalaria agents | UNIVERSITEIT GENT (BE) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312190-A1 | Such as 3-(N-hydroxyacetamido)-1-(3,4-dichlorophenyl)propylphosphonic acid; Antimalaria agents | SUB1, CBR1, NAT1 | MEN1 2263/4885KMT2A 2089/4885L3MBTL1 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.